Blog

New target antigen could make CAR-T possible for glioblastomas – FierceBiotech


FierceBiotech

New target antigen could make CART possible for glioblastomas
FierceBiotech
Surgery, radiation and chemotherapy just don't cut it against glioblastoma, a type of aggressive brain tumor with a dismal five-year survival rate. Survival is highest in younger people, at 19% for those aged 20 to 44, but it drops sharply with age

2018-03-01 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.